Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients

Daehun Kwag, MD, Byung Sik Cho, MD, PhD, Gi June Min, MD, Sung-Soo Park, Silvia Park, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD PhD, Ki-Seong Eom, MD, PhD, Yoo-Jin Kim, MD, PhD, Seok Lee, MD, PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD, PhD, Dong-Wook Kim, MD, Jong Wook Lee, MD, PhD, Hee-Je Kim, MD PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143361

Published: 2020

Journal Articles

Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry

Britta Hoechsmann, Regis Peffault De Latour, MD PhD, Anita Hill, Alexander Röth, MD, Timothy Devos, MD, Christopher Patriquin, Wen-Chien Chou, MD PhD, Deepak Jain, Ke Zu, Jong Wook Lee, MD, PhD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-136767

Published: 2020

Journal Articles

Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies

Regis Peffault De Latour, MD PhD, Jeffrey Szer, MBBS, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Jin Seok Kim, MD PhD, Caroline I. Piatek, MD, Alexander D. Kulagin, MD PhD, Anita Hill, Jimmy Wang, Ji Yu, Masayo Ogawa, MD FAAP, Hubert Schrezenmeier, Jong Wook Lee, MD, PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140777

Published: 2020

Journal Articles

Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks

Hubert Schrezenmeier, Jong Wook Lee, MD, PhD, Anita Hill, Vadim V Ptushkin, Viviani Pessoa, Rosario Notaro, Jimmy Wang, Masayo Ogawa, MD FAAP, Shinichiro Okamoto, MD PhD, Lily LL Wong, MD FRCPath, Regis Peffault De Latour, MD PhD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-142453

Published: 2020

Journal Articles

A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling

Gi June Min, MD, Byung Sik Cho, MD, PhD, Sung-Soo Park, MD, PhD, Silvia Park, MD PhD, Seung-Ah Yahng, MD, PhD, Young-Woo Jeon, MD PhD, Seung-Hwan Shin, MD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD PhD, Ki-Seong Eom, MD, PhD, Yoo-Jin Kim, MD, PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD, PhD, Dong-Wook Kim, MD, Jong Wook Lee, MD, PhD, Heeje Kim, MD PhD, Seok Lee, MD, PhD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-139234

Published: 2020

Journal Articles

Phase 3 Study of Danicopan, an Oral Complement Factor D Inhibitor, As Add-on Therapy to a C5 Inhibitor in Patients with Paroxysmal Nocturnal Hemoglobinuria with Clinically Evident Extravascular Hemolysis

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Antonio Risitano, Jong Wook Lee, MD, PhD, Mingjun Huang, PhD, Jun-Ichi Nishimura, MD PhD, Alejandra Ramirez-Santiago, Robert Brodsky

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-134388

Published: 2020

Journal Articles

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Anita Hill, MD PhD, Caroline I. Piatek, Régis Peffault de Latour, MD PhD, Lily LL Wong, MD FRCPath, Richard A. Wells, MD DPhil, Robert A. Brodsky, MD, Jin Seok Kim, MD PhD, Junichi Nishimura, MD PhD, Philip Kuriakose, MD, Rodrigo Pavani, Peng Liu, Stephan Ortiz, RPh, PhD, Hubert Schrezenmeier, MD, Jong-Wook Lee, MD PhD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 952.

https://doi.org/10.1182/blood-2019-128929

Published: 2019

Journal Articles

Comparison of Myeloablative (CyTBI, BuCy) Versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Low WT1 Expression Level at Transplant

Silvia Park, GI June MIN, MD, Sung-Soo Park, Seung-Ah Yahng, MD PhD, Young-Woo Jeon, MD PhD, Seung-Hwan Shin, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Byung-Sik Cho, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD, Hee-Je Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1973.

https://doi.org/10.1182/blood-2019-128306

Published: 2019

Journal Articles

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Austin Kulasekararaj, MBBS MDMRCP FRCPath, Antonio M. Risitano, MD PhD, Jaroslaw P. Maciejewski, MD PhD, Rosario Notaro, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA, Jong-Wook Lee, MD, Mingjun Huang, PhD, Michael Geffner, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 3514.

https://doi.org/10.1182/blood-2019-124748

Published: 2019

Journal Articles

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Antonio M. Risitano, MD PhD, Jong Wook Lee, MD PhD, Rosario Notaro, MD, Robert A. Brodsky, MD, Austin Kulasekararaj, MBBS MDMRCP FRCPath, Jaroslaw P. Maciejewski, MD PhD, Mingjun Huang, PhD, Michael Geffner, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 2226.

https://doi.org/10.1182/blood-2019-124837

Published: 2019

Journal Articles

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Anita Hill, MD PhD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Emilio Ojeda Gutierrez, Caroline I. Piatek, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Kensuke Usuki, Alberto Bosi, Robert A. Brodsky, MD, Masayo Ogawa, MD FAAP, Ji Yu, Stephan Ortiz, RPh, PhD, Alexander Röth, MD PhD, Jong-Wook Lee, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2231.

https://doi.org/10.1182/blood-2019-128746

Published: 2019

Journal Articles

Natural-Killer Cell Cytotoxicity Is a Diagnostic and Prognostic Marker in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Results from a Prospective Phase II Observational Study

Han Bi Lee, Jae-Ho Yoon, MD PhD, Gi June Min, MD, Sung-Soo Park, Silvia Park, Sung-Eun Lee, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Hee-Je Kim, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Jong Wook Lee, MD PhD

Blood (2019) 134 (Supplement_1): 2331.

https://doi.org/10.1182/blood-2019-129676

Published: 2019

Journal Articles

Physical and Psychological Impairments As Practical Frailty Markers in Elderly AML Fit for Intensive Chemotherapy; Interim Data of a Prospective Cohort Study

GI June MIN, MD, Byung Sik Cho, MD PhD, Sung-Soo Park, MD, Silvia Park, Young-Woo Jeon, MD PhD, Seung-Hwan Shin, MD PhD, Seung-Ah Yahng, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Seok-Goo Cho, MD PhD, Chang-Ki Min, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD, Hee-Je Kim, MD PhD

Blood (2019) 134 (Supplement_1): 3831.

https://doi.org/10.1182/blood-2019-123584

Published: 2019

Journal Articles

Poor Outcomes of HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation and High Ferritin Levels after a Reduced-Intensity Conditioning Regimen in Patients with Advanced Myelofibrosis

Han Bi Lee, Jae-Ho Yoon, MD PhD, Gi June Min, MD, Sung-Soo Park, Silvia Park, Sung-Eun Lee, MD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Hee-Je Kim, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Jong Wook Lee, MD PhD, Ki-Seong Eom, MD PhD

Blood (2019) 134 (Supplement_1): 5742.

https://doi.org/10.1182/blood-2019-130338

Published: 2019

Journal Articles

Genetic Characteristics and Clinical Outcomes of T-Cell Acute Lymphoblastic Leukemia; Myeloid-Suppressive Therapeutic Approach Based on Allogeneic Hematopoietic Cell Transplantation May Benefit in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Jae-Ho Yoon, MD PhD, Han Bi Lee, Gi June Min, MD, Sung-Soo Park, Silvia Park, Byung Sik Cho, MD PhD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Hee-Je Kim, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Jong Wook Lee, MD PhD, Seok Lee, MD PhD

Blood (2019) 134 (Supplement_1): 1470.

https://doi.org/10.1182/blood-2019-129870

Published: 2019

Journal Articles

Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia

Jee Yon Shin, Sung-Soo Park, Gi June Min, MD, Silvia Park, Sung-Eun Lee, MD, Jae-Ho Yoon, MD PhD, Seung-Hwan Shin, MD PhD, Sung-Eun Lee, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang-Ki Min, MD PhD, Hee-Je Kim, MD PhD, Seok-Goo Cho, MD PhD, Jong-Wook Lee, MD

Blood (2019) 134 (Supplement_1): 4619.

https://doi.org/10.1182/blood-2019-130419

Published: 2019

Journal Articles

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Gi June Min, MD, Hee-Je Kim, MD PhD, Sung-Soo Park, MD, Silvia Park, Young-Woo Jeon, MD PhD, Seung-Ah Yahng, MD PhD, Seung-Hwan Shin, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Byung Sik Cho, MD PhD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3260.

https://doi.org/10.1182/blood-2019-124275

Published: 2019

Journal Articles

Randomized Trial of Two Dosages of Rabbit Antithymocyte Globulin in Patients with Aplastic Anemia

Atsushi Narita, MD PhD, Xiaofan Zhu, PhD, Hideki Muramatsu, MD PhD, Xiaojuan Chen, Ye Guo, Wenyu Yang, Jingliao Zhang, MD, Fang Liu, Jun Ho Jang, MD PhD, Hoon Kook, MD PhD, Hawk Kim, MD PhD, Kensuke Usuki, MD PhD, Hirohito Yamazaki, MD PhD, Yoshiyuki Takahashi, MD, PhD, Shinji Nakao, MD PhD, Jong-Wook Lee, MD PhD, Seiji Kojima, MD PhD

Blood (2018) 132 (Supplement 1): 3873.

https://doi.org/10.1182/blood-2018-99-111323

Published: 2018

Journal Articles

Measurable Residual Disease Assay with WT1 Expression in Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation; Optimal Threshold, Time Points, and Candidates

Byung Sik Cho, MD PhD, GI June MIN, MD, Heeje Kim, MD PhD, Seug Yun Yoon, MD, Sung-Soo Park, MD, Silvia Park, MD PhD, Seung-Ah Yahng, MD PhD, Young-Woo Jeon, MD PhD, Seung-Hwan Shin, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD PhD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Dong-Wook Kim, MD PhD, Jong-Wook Lee, MD PhD

Blood (2018) 132 (Supplement 1): 2759.

https://doi.org/10.1182/blood-2018-99-110042

Published: 2018

Journal Articles

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Yasutaka Ueda, MD PhD, Hiroyuki Takamori, MD, Jun-Ho Jang, MD PhD, Chezi Ganzel, MD, Saskia Langemeijer, MD PhD, Makiko Osato, MS, Petra Muus, MD PhD, Jong-Wook Lee, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 2323.

https://doi.org/10.1182/blood-2018-99-111230

Published: 2018

NARROW

Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients

Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry

Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies

Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks

A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling

Phase 3 Study of Danicopan, an Oral Complement Factor D Inhibitor, As Add-on Therapy to a C5 Inhibitor in Patients with Paroxysmal Nocturnal Hemoglobinuria with Clinically Evident Extravascular Hemolysis

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Comparison of Myeloablative (CyTBI, BuCy) Versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Low WT1 Expression Level at Transplant

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Natural-Killer Cell Cytotoxicity Is a Diagnostic and Prognostic Marker in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Results from a Prospective Phase II Observational Study

Physical and Psychological Impairments As Practical Frailty Markers in Elderly AML Fit for Intensive Chemotherapy; Interim Data of a Prospective Cohort Study

Poor Outcomes of HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation and High Ferritin Levels after a Reduced-Intensity Conditioning Regimen in Patients with Advanced Myelofibrosis

Genetic Characteristics and Clinical Outcomes of T-Cell Acute Lymphoblastic Leukemia; Myeloid-Suppressive Therapeutic Approach Based on Allogeneic Hematopoietic Cell Transplantation May Benefit in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Randomized Trial of Two Dosages of Rabbit Antithymocyte Globulin in Patients with Aplastic Anemia

Measurable Residual Disease Assay with WT1 Expression in Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation; Optimal Threshold, Time Points, and Candidates

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only